What does this research mean for the field?

Variability in commercial thromboplastins used for prothrombin time testing creates uncertainty in anticoagulation intensity, exposing patients on long-term oral anticoagulant therapy to unnecessary risks of bleeding or thromboembolism. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To evaluate how laboratory variations in prothrombin-time ratios resulting from differences in commercial thromboplastins influence the management and safety of oral anticoagulant therapy.

September 2, 1993New England Journal of MedicineOpen Access

Effect of Laboratory Variation in the Prothrombin-Time Ratio on the Results of Oral Anticoagulant Therapy

View Full Paper

Ask AI

Bookmark

Why the study?

Does variability in commercial thromboplastins affect the risk of bleeding or thromboembolism in patients receiving long-term anticoagulant therapy?

Population

Patients receiving long-term anticoagulant therapy

Design

Other

Authors

MEMark H. EckmanGeneral / Preventive / Lipids HLHerbert J. LevineWesleyan University SPStephen G. PaukerGeneral / Preventive / Lipids

Discussion

Member takes

Implication

Alerts clinicians to INR inconsistencies from thromboplastin variability; leaves open the magnitude of associated bleeding and thromboembolic risks.

Key Points

To evaluate how laboratory variations in prothrombin-time ratios resulting from differences in commercial thromboplastins influence the management and safety of oral anticoagulant therapy.
Assessed the analytical consistency of commercial thromboplastins utilized in laboratory prothrombin-time determination for patients undergoing long-term oral anticoagulation.
Variability among commercial thromboplastin reagents introduces substantial uncertainty regarding the true intensity of anticoagulation.
Inconsistent laboratory prothrombin-time results expose patients receiving maintenance anticoagulation to avoidable risks of bleeding and thromboembolic events.

Structured PICO

Does variability in commercial thromboplastins affect the risk of bleeding or thromboembolism in patients receiving long-term anticoagulant therapy?

Population

Patients receiving long-term anticoagulant therapy

Intervention

Commercial thromboplastins used to determine prothrombin time

Outcome

Risks of bleeding or thromboembolismhard clinical

Variability in commercial thromboplastins used for prothrombin time testing may expose patients on long-term anticoagulants to unnecessary bleeding or thromboembolic risks.

Cite This Study

Eckman et al. (1993) studied this question.

synapsesocial.com/papers/6a1e75617f6e8bbb2368f05e https://doi.org/10.1056/nejm199309023291005

View Full Paper

Ask AI

Bookmark

Implication

Alerts clinicians to INR inconsistencies from thromboplastin variability; leaves open the magnitude of associated bleeding and thromboembolic risks.

Effect of Laboratory Variation in the Prothrombin-Time Ratio on the Results of Oral Anticoagulant Therapy

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Effect of Laboratory Variation in the Prothrombin-Time Ratio on the Results of Oral Anticoagulant Therapy

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider